These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

351 related items for PubMed ID: 8653697

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor.
    Lal G, Ash C, Hay K, Redston M, Kwong E, Hancock B, Mak T, Kargman S, Evans JF, Gallinger S.
    Cancer Res; 2001 Aug 15; 61(16):6131-6. PubMed ID: 11507063
    [Abstract] [Full Text] [Related]

  • 3. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos.
    Jacoby RF, Cole CE, Tutsch K, Newton MA, Kelloff G, Hawk ET, Lubet RA.
    Cancer Res; 2000 Apr 01; 60(7):1864-70. PubMed ID: 10766173
    [Abstract] [Full Text] [Related]

  • 4. Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) mice.
    Hansen-Petrik MB, McEntee MF, Jull B, Shi H, Zemel MB, Whelan J.
    Cancer Res; 2002 Jan 15; 62(2):403-8. PubMed ID: 11809688
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice.
    Swamy MV, Patlolla JM, Steele VE, Kopelovich L, Reddy BS, Rao CV.
    Cancer Res; 2006 Jul 15; 66(14):7370-7. PubMed ID: 16849589
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Molecular analysis of sulindac-resistant adenomas in familial adenomatous polyposis.
    Keller JJ, Offerhaus GJ, Drillenburg P, Caspers E, Musler A, Ristimäki A, Giardiello FM.
    Clin Cancer Res; 2001 Dec 15; 7(12):4000-7. PubMed ID: 11751493
    [Abstract] [Full Text] [Related]

  • 10. Modulation of experimental colon tumorigenesis by types and amounts of dietary fatty acids.
    Rao CV, Hirose Y, Indranie C, Reddy BS.
    Cancer Res; 2001 Mar 01; 61(5):1927-33. PubMed ID: 11280748
    [Abstract] [Full Text] [Related]

  • 11. Genotype-phenotype correlation in murine Apc mutation: differences in enterocyte migration and response to sulindac.
    Mahmoud NN, Bilinski RT, Churchill MR, Edelmann W, Kucherlapati R, Bertagnolli MM.
    Cancer Res; 1999 Jan 15; 59(2):353-9. PubMed ID: 9927046
    [Abstract] [Full Text] [Related]

  • 12. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor.
    Rao CV, Indranie C, Simi B, Manning PT, Connor JR, Reddy BS.
    Cancer Res; 2002 Jan 01; 62(1):165-70. PubMed ID: 11782374
    [Abstract] [Full Text] [Related]

  • 13. Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors.
    Zweifel BS, Davis TW, Ornberg RL, Masferrer JL.
    Cancer Res; 2002 Nov 15; 62(22):6706-11. PubMed ID: 12438270
    [Abstract] [Full Text] [Related]

  • 14. [The transgenic mouse model of familial polyposis coli].
    Fehmann HC, Eissele R.
    Z Gastroenterol; 1997 Nov 15; 35(11):1035-7. PubMed ID: 9490555
    [No Abstract] [Full Text] [Related]

  • 15. Cyclooxygenase 2 is up-regulated and localized to macrophages in the intestine of Min mice.
    Hull MA, Booth JK, Tisbury A, Scott N, Bonifer C, Markham AF, Coletta PL.
    Br J Cancer; 1999 Mar 15; 79(9-10):1399-405. PubMed ID: 10188882
    [Abstract] [Full Text] [Related]

  • 16. NS-398 inhibits tumor growth and liver metastasis of colon cancer through induction of apoptosis and suppression of the plasminogen activation system in a mouse model.
    Nishikawa M, Stapleton PP, Freeman TA, Gaughan JP, Matsuda T, Daly JM.
    J Am Coll Surg; 2004 Sep 15; 199(3):428-35. PubMed ID: 15325613
    [Abstract] [Full Text] [Related]

  • 17. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis.
    Reddy BS, Hirose Y, Lubet R, Steele V, Kelloff G, Paulson S, Seibert K, Rao CV.
    Cancer Res; 2000 Jan 15; 60(2):293-7. PubMed ID: 10667579
    [Abstract] [Full Text] [Related]

  • 18. Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells.
    Sun Y, Tang XM, Half E, Kuo MT, Sinicrope FA.
    Cancer Res; 2002 Nov 01; 62(21):6323-8. PubMed ID: 12414664
    [Abstract] [Full Text] [Related]

  • 19. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction.
    Piazza GA, Rahm AK, Finn TS, Fryer BH, Li H, Stoumen AL, Pamukcu R, Ahnen DJ.
    Cancer Res; 1997 Jun 15; 57(12):2452-9. PubMed ID: 9192825
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis.
    Reddy BS, Rao CV, Seibert K.
    Cancer Res; 1996 Oct 15; 56(20):4566-9. PubMed ID: 8840961
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.